complementari
altern
medicin
cam
therapi
sought
encompass
wide
rang
approach
includ
two
broad
categori
exogen
chemic
herbal
supplement
vitamin
plant
extract
natur
selftherapi
nst
techniqu
includ
relax
medit
prayer
hypnosi
biofeedback
physic
strengthen
use
herbal
medicin
began
ancient
china
time
xia
dynasti
india
vedic
period
revolut
natur
scienc
evidencebas
medicin
divid
western
eastern
medicin
appear
widen
cam
reach
increas
popular
western
countri
year
popul
ageold
system
herbal
medicin
reviv
daytoday
practic
longlast
cur
effect
easi
avail
natur
way
heal
less
sideeffect
today
herbal
medicin
gain
import
expand
throughout
world
widespread
use
cam
emphas
among
peopl
chronic
diseas
sinc
promot
greater
person
control
health
decis
empow
peopl
manag
chronic
condit
help
avoid
dissatisfact
often
associ
convent
health
care
cam
believ
safer
better
standard
medic
practic
natur
base
religi
philosoph
strongli
felt
concept
well
health
treatment
herbal
medicin
concentr
reestablish
reinforc
natur
heal
process
well
despit
increas
popular
commun
use
cam
physician
patient
limit
physician
know
littl
cam
patient
avoid
discuss
cam
fear
receiv
indiffer
moreov
physician
use
focu
attent
potenti
toxic
even
though
identif
toxic
herbal
prepar
often
difficult
patient
gener
selfmed
may
withhold
inform
toxic
hepat
common
advers
reaction
result
use
cam
often
associ
concomit
consumpt
hepatotox
ingredi
acetaminophen
nonsteroid
antiinflammatori
agent
hepatotox
herbal
ingredi
physician
health
care
provid
need
becom
familiar
product
recogn
potenti
interact
convent
drug
herbal
consid
actual
diffus
botan
medicin
use
tradit
herbalist
indigen
healer
worldwid
prevent
treatment
liver
diseas
clinic
research
centuri
confirm
efficaci
sever
plant
treatment
liver
diseas
fact
patient
chronic
liver
diseas
seek
primari
adjunct
herbal
treatment
surpris
particularli
silymarin
extract
milk
thistl
popular
product
taken
subject
liver
diseas
especi
hepat
c
viru
infect
seeff
et
al
found
outpati
diagnosi
liver
diseas
use
form
cam
herbal
product
often
use
improv
wellb
qualiti
life
amelior
side
effect
patient
antivir
treatment
fatigu
irrit
depress
lessen
symptom
might
permit
higher
complianc
avoid
need
limit
dose
final
withdraw
interferon
systemat
review
use
cam
chronic
hepat
c
conduct
coon
ernst
author
cite
fourteen
random
clinic
trial
consid
combin
use
herbal
product
interferonalfa
antivir
treatment
although
difficulti
extrapol
interpret
result
differ
methodolog
limit
consid
studi
author
found
sever
herbal
product
supplement
vitamin
e
thymic
extract
zinc
tradit
chines
medicin
glycyrrhiza
glabra
oxymatrin
could
exert
potenti
virolog
biochem
effect
treatment
chronic
hepat
c
infect
greater
clearanc
hcvrna
normal
liver
enzym
shown
variou
studi
use
cam
could
predict
social
cultur
geograph
factor
sex
age
higher
educ
level
marriag
statu
patient
associ
differ
use
herbal
product
aim
studi
describ
potenti
role
benefit
limit
known
widespread
herbal
product
chronic
liver
diseas
conduct
updat
research
pubm
medlin
order
refer
recent
articl
issu
quercetin
one
major
flavonoid
repres
class
natur
occur
polyphenol
compound
ubiquit
present
photosynthesis
cell
intak
flavon
flavonol
determin
mgday
quercetin
main
flavonol
present
diet
repres
intak
quercetin
found
fruit
appl
veget
especi
onion
variou
way
supplement
quercetin
possibl
includ
pure
supplement
diet
intervent
use
food
compon
high
quercetin
content
supplement
usual
contain
aglycon
form
quercetin
wherea
food
compon
normal
compris
high
amount
variou
quercetin
deriv
might
better
biolog
avail
aglycon
anoth
advantag
dietari
supplement
versu
convent
supplement
might
better
complianc
especi
longterm
use
absorpt
quercetin
consider
enhanc
conjug
sugar
group
facilit
uptak
mean
carriermedi
transport
quercetin
glycosid
often
becom
hydrolys
intracellular
absorpt
quercetin
becom
metabol
variou
organ
includ
small
intestin
colon
liver
kidney
metabolit
form
small
intestin
liver
mainli
result
phase
ii
metabol
biotransform
enzym
therefor
includ
methyl
sulphat
glucuronid
form
moreov
bacteri
ring
fission
aglycon
occur
small
intestin
colon
result
breakdown
backbon
structur
quercetin
subsequ
format
smaller
phenol
quercetin
appear
mani
benefici
effect
human
health
includ
cardiovascular
protect
anticanc
activ
antiulc
antiallergi
activ
cataract
prevent
antiinflammatori
effect
quercetin
shown
excel
vitro
antioxid
within
flavonoid
famili
potent
scaveng
ro
reactiv
oxygen
speci
includ
pathogenesi
progress
ald
associ
free
radic
injuri
oxid
stress
could
partial
attenu
antioxid
free
radic
scaveng
lipid
metabol
disord
oxid
stress
play
import
role
develop
progress
ald
mitochondria
compart
presum
main
sourc
suscept
target
intracellular
ro
hypothesi
quercetin
could
prevent
ethanolinduc
oxid
damag
hepatocyt
investig
anim
studi
prophylaxi
quercetinamelior
ethanolstimul
mitochondri
dysfunct
manifest
decreas
membran
potenti
induc
permeabl
transit
though
suppress
glutathion
deplet
enzymat
inactiv
manganes
superoxid
dismutas
glutathion
peroxidas
ro
overgener
lipid
peroxid
mitochondria
quercetin
thu
may
protect
rat
especi
hepat
mitochondria
chronic
ethanol
toxic
hypolipidem
effect
antioxid
role
highlight
promis
prevent
strategi
ald
natur
occur
phytochem
quercetin
tend
downregul
ethanolinduc
express
glutathionin
peroxidas
furthermor
tend
reduc
express
induc
ethanol
downregul
express
presenc
ethanol
could
permit
explain
dna
demethyl
associ
upregul
gene
express
experiment
ald
anoth
studi
evalu
effect
quercetin
paramet
classic
associ
alcohol
liver
injuri
lactat
dehydrogenas
ldh
aspart
transaminas
ast
malondialdehyd
mda
glutathion
gsh
superoxid
dismutas
sod
catalas
cat
order
address
alter
cell
damag
antioxid
state
quercetin
intervent
ethanolintox
mm
h
rat
primari
hepatocyt
simultan
treat
pretreat
h
posttreat
h
quercetin
toxic
insult
ethanol
hepatocyt
challeng
quercetin
biochem
paramet
almost
return
level
control
group
hepatocyt
treat
quercetin
dose
h
ethanol
exposur
recent
studi
elucid
also
neuroprotect
effect
quercetin
alcoholinduc
neuropathi
modul
membranebound
inorgan
phosphat
enzym
inhibit
releas
oxidoinflammatori
mediat
malondialdehyd
mda
myeloperoxidas
mpo
mpo
nitric
oxid
conclus
pretreat
quercetin
provid
protect
ethanolinduc
oxid
stress
hepatocyt
may
use
new
natur
drug
prevent
andor
treatment
ald
antioxid
significantli
reduc
oxid
stress
induc
ethanol
intox
increas
membran
integr
also
increas
organ
regener
nonalcohol
fatti
liver
diseas
nafld
common
caus
chronic
liver
diseas
unit
state
repres
hepat
manifest
metabol
derang
known
metabol
syndrom
insulin
resist
play
major
role
nonalcohol
fatti
liver
diseas
includ
varieti
histolog
condit
rang
liver
steatosi
steatohepat
fibrosi
hepatocarcinoma
character
increas
accumulationdeposit
fat
within
liver
associ
alter
hepat
system
inflammatori
state
hepatocyt
primari
cell
cultur
expos
high
glucos
insulin
linol
acid
concentr
respond
lipid
accumul
oxid
stress
cell
death
regard
role
quercetin
nafld
show
mice
fed
western
diet
chronic
dietari
intak
quercetin
reduc
liver
fat
accumul
improv
system
paramet
relat
metabol
syndrom
probabl
mainli
decreas
oxid
stress
reduc
express
gene
relat
steatosi
anoth
studi
aim
examin
hypoglycem
insulinsensit
capac
onion
peel
extract
ope
contain
high
content
quercetin
high
fat
dietstreptozotocininduc
diabet
rat
elucid
mechan
insulinsensit
effect
ope
might
improv
glucos
respons
insulin
resist
associ
diabet
allevi
metabol
dysregul
free
fatti
acid
suppress
oxid
stress
upregul
glucos
uptak
peripher
tissu
andor
downregul
inflammatori
gene
express
liver
moreov
case
ope
show
greater
potenc
pure
quercetin
equival
find
provid
basi
use
onion
peel
improv
insulin
insensit
diabet
hepatocyt
normal
rat
decreas
de
novo
fatti
acid
tag
synthesi
induc
quercetin
repres
potenti
mechan
contribut
report
hypotriacylglycerolem
effect
agent
hepat
respons
chronic
noxiou
stimuli
may
lead
liver
fibrosi
preneoplast
cirrhot
liver
fibrogen
cell
activ
respons
varieti
cytokin
growth
factor
inflammatori
mediat
involv
member
epiderm
growth
factor
famili
process
suggest
amphiregulin
epiderm
growth
factor
receptor
egfr
ligand
specif
induc
upon
liver
injuri
recent
studi
investig
effect
quercetin
amphiregulinegfr
signal
activ
downstream
pathway
lead
cell
growth
quercetinamelior
activ
surviv
pathway
downregul
express
gene
relat
inflamm
precancer
condit
suppress
amphiregulinegfr
signal
may
contribut
effect
phytochem
exert
antivir
activ
may
play
potenti
therapeut
role
hepat
c
viru
hcv
infect
aspect
investig
sever
studi
park
et
al
investig
antivir
activ
hcvinfect
patient
deriv
five
quercetin
deriv
show
select
antivir
activ
hcv
replicon
cellbas
assay
recent
studi
studi
quercetin
potenti
nontox
antihcv
agent
reduc
viral
product
inhibit
heat
shock
protein
essenti
hcv
replic
found
quercetin
inhibit
activ
specif
dosedepend
manner
vitro
catalysi
assay
moreov
analyz
subgenom
hcv
rna
replicon
system
quercetin
seem
exert
adjunct
effect
inhibit
hcv
rna
replic
product
hcv
infecti
cell
cultur
system
hcvcc
analyz
focusform
unit
reduct
assay
hcv
rna
realtim
pcr
inhibitori
effect
quercetin
also
obtain
use
model
system
substrat
introduc
cell
provid
evid
inhibit
vivo
could
direct
involv
hcv
protein
work
demonstr
quercetin
direct
inhibitori
effect
hcv
proteas
recent
paper
discuss
effect
quercetin
hbv
replic
import
glucosid
structur
quercetin
deriv
exercis
biolog
action
hbv
replic
thirteen
flavon
glucosid
herb
euphorbia
humifusa
isol
among
five
compound
includ
show
antihbv
activ
vitro
antihbv
activ
close
relat
parent
structur
compound
agigenin
luteolin
quercetin
well
number
glucosid
flavon
monoglucosid
flavon
diglucosid
structur
agent
also
influenc
cytotox
flavon
flavon
monoglucosid
flavon
diglucosid
addit
substitut
acyl
group
glucosid
may
import
keep
antihbv
activ
galloyl
feruloyl
coumaroyl
quercetin
show
activ
hbeag
secret
limit
might
due
absenc
saccharid
group
structur
curcumin
lowmolecularweight
polyphenol
deriv
rhizom
turmer
curcuma
longa
repres
yellow
pigment
wide
use
color
agent
spice
mani
food
variou
benefici
pharmacolog
effect
includ
antioxid
antiinflammatori
anticarcinogen
hypocholesterolem
antibacteri
antispasmod
anticoagul
hepatoprotect
activ
phase
clinic
trial
shown
curcumin
safe
even
high
dose
gday
human
exhibit
poor
bioavail
despit
promis
biolog
effect
curcumin
low
plasma
tissu
level
curcumin
due
poor
oral
bioavail
absorpt
rapid
metabol
system
elimin
rodent
human
may
respons
unfavor
pharmacokinet
molecul
improv
bioavail
curcumin
numer
approach
undertaken
approach
involv
first
use
adjuv
like
piperin
interfer
glucuronid
second
use
liposom
curcumin
third
curcumin
nanoparticl
fourth
use
curcumin
phospholipid
complex
fifth
use
structur
analogu
curcumin
eg
liver
fibrosi
explain
increas
deposit
extracellular
matrix
ecm
chronic
alcohol
abus
one
main
caus
liver
fibrosi
ingest
polyunsatur
fatti
acid
pufa
togeth
alcohol
aggrav
toxic
alcohol
degre
abnorm
ecm
degrad
depend
ratio
activ
matrix
metalloproteinas
mmp
tissu
inhibitor
metalloproteinas
timp
recent
work
studi
influenc
bisdesmethoxi
curcumin
analog
bdmca
express
mmp
timp
alcohol
deltapufainduc
liver
toxic
administr
bdmca
significantli
decreas
level
collagen
timp
posit
modul
express
mmp
studi
conclud
bdmca
influenc
mmp
timp
express
act
effici
antifibrot
agent
demonstr
potenti
protect
effect
curcumin
pretreat
ethanolinduc
hepatocyt
oxid
damag
emphasi
heme
induct
ethanol
exposur
result
sustain
malondialdehyd
mda
elev
glutathion
gsh
deplet
evid
releas
cellular
lactat
dehydrogenas
ldh
aspart
aminotransferas
ast
significantli
amelior
curcumin
pretreat
addit
dose
timedepend
induct
involv
hepatoprotect
effect
curcumin
curcumin
exert
hepatoprotect
properti
ethanol
involv
induct
provid
new
insight
pharmacolog
target
curcumin
prevent
alcohol
liver
diseas
studi
mechan
curcuminattenu
inflamm
liver
patholog
earli
stage
alcohol
liver
diseas
femal
spraguedawley
rat
divid
four
group
treat
ethanol
curcumin
via
intragastr
tube
week
control
group
treat
distil
water
ethanol
group
treat
ethanol
gkg
bw
treatment
group
fed
ethanol
supplement
curcumin
mgkg
bw
liver
histopatholog
ethanol
group
reveal
mildtomoder
steatosi
mild
necroinflamm
hepat
mda
hepatocyt
apoptosi
nfkappab
activ
increas
significantli
ethanoltr
group
compar
control
curcumin
treatment
result
improv
liver
patholog
decreas
elev
hepat
mda
inhibit
nfkappab
activ
mgkg
bw
curcumin
treatment
also
reveal
trend
decreas
hepatocyt
apoptosi
howev
result
sod
activ
ppargamma
protein
express
show
differ
among
group
conclus
curcumin
improv
liver
histopatholog
earli
stage
ethanolinduc
liver
injuri
reduct
oxid
stress
inhibit
nfkappab
activ
anim
studi
demonstr
capac
curcumin
improv
liver
histolog
nafld
nash
model
induc
highfat
diet
combin
carbon
tetrachlorid
rat
success
treat
curcumin
curcumin
deriv
result
show
remark
reduct
serum
alt
ul
ast
ul
rat
treat
curcumin
deriv
degre
fibrosi
also
significantli
allevi
reduct
gene
transcript
tnfalpha
nfkappab
hmgcoa
mechan
propos
wich
curcumin
exercis
benefici
effect
nash
result
studi
indic
moreov
watersolubl
curcumin
deriv
display
superior
bioavail
parent
curcumin
effect
improv
lipid
metabol
delay
progress
hepat
fibrosi
rat
steatohepat
interestingli
also
demonstr
activ
effect
ldl
revers
curcumin
hypocholesterolem
action
curcumin
report
numer
studi
curcumin
seem
reduc
serum
cholesterol
concentr
increas
hepat
express
ldl
receptor
block
ldl
oxid
increas
bile
acid
secret
faecal
excret
cholesterol
repress
express
gene
involv
cholesterol
biosynthesi
protect
liver
injuri
fibrogenesi
curcumin
induc
apoptosi
block
prolifer
hepat
stellat
cell
hsc
via
activ
inhibit
extracellular
matrix
format
downregul
express
ldl
receptor
induc
increas
fatstor
capac
hsc
may
therebi
restor
protect
function
prove
therapeut
usag
prevent
liver
steatosi
fibrosi
italian
studi
test
whether
administr
curcumin
limit
fibrogen
evolut
murin
model
nonalcohol
steatohepat
demonstr
curcumin
decreas
intrahepat
gene
express
monocyt
chemoattract
procollagen
type
tissu
inhibitor
metalloproteas
timp
togeth
protein
level
alphasmooth
muscl
actin
marker
fibrogen
cell
addit
curcumin
reduc
gener
reactiv
oxygen
speci
cultur
hsc
inhibit
secret
basal
condit
induct
oxid
stress
studi
propos
curcumin
administr
effect
limit
develop
progress
fibrosi
mice
experiment
steatohepat
reduc
secret
oxid
stress
cultur
stellat
cell
high
consumpt
dietari
fructos
import
contributori
factor
develop
hepat
steatosi
insulin
leptin
resist
effect
curcumin
fructoseinduc
hypertriglyceridemia
liver
steatosi
prevent
mechan
rat
investig
curcumin
reduc
serum
insulin
leptin
level
fructosef
rat
protect
fructoseinduc
hypertriglyceridemia
hepat
steatosi
inhibit
hepat
protein
tyrosin
phosphatas
subsequ
improv
insulin
leptin
sensit
liver
rat
inhibitori
properti
may
repres
promis
role
curcumin
treat
fructoseinduc
hepat
steatosi
induc
hepat
insulin
leptin
resist
curcumin
known
exert
antivir
activ
influenza
viru
adenoviru
coxsackieviru
human
immunodefici
viru
howev
remain
determin
whether
curcumin
inhibit
replic
hepat
c
viru
hcv
studi
show
curcumin
decreas
hcv
gene
express
via
suppress
activ
nfkappab
pathway
combin
curcumin
ifnalpha
exert
profound
inhibitori
effect
hcv
replic
result
indic
curcumin
suppress
hcv
replic
vitro
may
potenti
use
novel
antihcv
reagent
hepat
b
viru
hbv
infect
liver
use
cell
host
gene
express
propag
therefor
sinc
target
host
factor
essenti
hbv
gene
express
could
repres
potenti
antivir
strategi
curcumin
treatment
could
complement
antivir
activ
nucleotidenucleosid
analogu
consid
gold
standard
antihbv
therapi
combin
lamivudin
curcumin
treatment
result
enhanc
suppress
hbv
express
compar
nontreat
cell
result
suggest
curcumin
may
work
synergist
current
antihbv
nucleotidenucleosid
analog
combin
may
result
better
suppress
hbv
moreov
curcumin
inhibit
hbv
gene
express
replic
downregul
starvationinduc
protein
initi
gluconeogenesi
cascad
shown
robustli
coactiv
hbv
transcript
silybum
marianum
also
known
milk
thistl
member
asteracea
famili
well
recogn
hepatoprotect
herbal
medicin
silymarin
lipophil
extract
milk
thistl
seed
compos
three
isom
flavonolignan
silybin
silydianin
silychristin
two
flavonoid
taxifolin
quercetin
silymarin
reveal
poor
absorpt
rapid
metabol
ultim
poor
oral
bioavail
optimum
silymarin
bioavail
issu
solubl
permeabl
metabol
excret
must
address
array
method
describ
recent
year
improv
bioavail
includ
complex
solid
dispers
method
format
microparticl
nanoparticl
selfmicroemulsifi
drug
deliveri
system
micel
liposom
phytosom
silymarin
possess
variou
pharmacolog
activ
includ
hepatoprotect
antioxid
antiinflammatori
anticanc
cardioprotect
effect
silybum
marianum
wellresearch
plant
treatment
liver
diseas
silymarin
shown
varieti
antiinflammatori
effect
liver
includ
mast
cell
stabil
inhibit
neutrophil
migrat
kupffer
cell
inhibit
silymarin
commonli
prescrib
case
cirrhosi
viral
hepat
hepatocyt
model
propos
platform
screen
herbal
compon
ethanol
hepatotox
nanosilibinin
first
time
found
perform
signific
protect
ethanolinduc
hepatotox
silibinin
normal
particl
could
inhibit
toxic
protect
nanosilibinin
might
relat
high
bioavail
compar
normal
insolubl
silibinin
could
act
antioxid
antisteatosi
agent
ethanolinduc
hepatotox
affect
silymarin
level
serum
alt
ggt
ethanolinduc
hepatotox
albino
rat
also
test
eighteen
male
albino
rat
age
week
weigh
gm
divid
group
rat
group
control
group
b
rat
take
ethanol
dose
ml
gm
gmday
group
c
take
ethanol
silymarin
dose
gmday
gmday
respect
week
silymarin
tend
normal
liver
function
test
alcohol
liver
diseas
acut
ethanol
administr
caus
promin
hepat
microvesicular
steatosi
mild
necrosi
elev
serum
alt
activ
induc
signific
decreas
hepat
glutathion
conjunct
enhanc
lipid
peroxid
oxid
stress
increas
hepat
tnf
necrosi
factoralpha
product
supplement
standard
silymarin
antioxid
antiinflamm
properti
decreas
tnf
product
attenu
advers
chang
induc
acut
ethanol
administr
view
nontox
natur
may
develop
effect
therapeut
agent
alcoholinduc
liver
diseas
antioxid
stress
antiinflammatori
featur
silymarin
show
signific
hypocholesterolem
effect
compar
diet
model
high
fatdiet
hfd
moreov
silymarin
significantli
reduc
tg
level
compar
hfd
group
elev
transaminas
usual
reflect
necrosi
hepatocyt
silymarin
alt
level
specif
index
hepat
necrosi
particularli
reduc
assum
oxid
stress
lead
chronic
liver
damag
loguercio
et
al
conduct
studi
antioxid
activ
silybin
conjug
vitamin
e
phospholipid
eightyf
patient
divid
group
affect
nonalcohol
fatti
liver
diseas
group
hcvrelat
chronic
hepat
associ
nonalcohol
fatti
liver
diseas
group
b
nonrespond
antivir
treatment
treatment
consist
silybinvitamin
ephospholipid
treatment
group
show
signific
reduct
ultrasonograph
score
liver
steatosi
liver
enzym
level
hyperinsulinemia
index
liver
fibrosi
show
improv
treat
individu
signific
correl
among
index
fibrosi
bodi
mass
index
insulinemia
plasma
level
transform
growth
factorbeta
tumor
necrosi
factoralpha
degre
steatosi
gammaglutamyl
transpeptidas
observ
data
suggest
silybin
conjug
vitamin
e
phospholipid
could
use
complementari
approach
treatment
patient
chronic
liver
damag
silymarin
purifi
flavonolignan
recent
demonstr
inhibit
hepat
c
viru
hcv
infect
vitro
vivo
silymarin
show
antivir
effect
hepat
c
viru
cell
cultur
hcvcc
infect
includ
inhibit
viru
entri
rna
protein
express
infecti
viru
product
silymarin
block
hcvcc
bind
cell
inhibit
entri
sever
viral
pseudoparticl
pp
fusion
hcvpp
liposom
silymarin
also
block
celltocel
spread
viru
pegyl
interferon
pegifn
plu
ribavirin
therapi
current
treatment
patient
chronic
hepat
c
main
goal
therapi
achiev
sustain
virolog
respons
svr
defin
undetect
hcvrna
peripher
blood
determin
sensit
polymeras
chain
reaction
techniqu
week
end
treatment
goal
practic
equival
erad
hcv
infect
cure
underli
hcvinduc
liver
diseas
therapi
effect
half
patient
import
sideeffect
resist
high
cost
relat
therapi
silymarin
inhibit
hcv
rna
dosedepend
manner
hcv
core
express
thank
direct
effect
hcv
core
activ
jakstat
pathway
result
inhibit
hcv
core
gene
phosphoryl
tyrosin
serin
silymarin
silibinin
inhibit
genotyp
rnadepend
rna
polymeras
rdrp
activ
concentr
time
higher
requir
antihcvcc
effect
furthermor
silymarin
ineffici
activ
genotyp
although
inhibit
vitro
polymeras
activ
demonstr
mechan
silymarin
antivir
action
appear
includ
block
viru
entri
transmiss
target
host
cell
anoth
studi
patient
chronic
hepat
c
perform
silymarin
mgday
month
improv
serum
hcvrna
titer
serum
aminotransferas
alt
ast
hepat
fibrosi
patient
qualiti
life
treatment
nine
patient
found
neg
hcvrna
statist
signific
improv
result
liver
fibrosi
marker
found
fibrosi
group
antioxid
antiinflammatori
action
sylimarin
could
result
use
reduc
hepat
inflamm
chronic
liver
diseas
includ
hcvrelat
damag
hypothes
decreas
hepat
inflammationdu
direct
indirect
effect
silymarin
decreas
viral
replic
potenti
induc
longterm
benefit
infect
liver
sinc
oxid
stress
may
play
pathogenet
role
chronic
hepat
c
sustain
virolog
respons
antivir
therapi
limit
genotyp
infect
doubleblind
studi
perform
patient
treat
pegyl
interferon
ribavirin
order
assess
efficaci
supplement
antioxid
flavonoid
silymarin
silymarin
group
rapid
decreas
malondialdehyd
level
well
mark
decreas
superoxid
dismutas
increas
myeloperoxidas
activ
twelv
month
treatment
found
particular
alanin
aminotransferas
normal
versu
control
case
sustain
virolog
respons
occur
versu
patient
recent
data
discuss
role
silymarin
hepat
b
report
silymarin
benefici
effect
earli
stage
liver
pathogenesi
prevent
delay
liver
carcinogenesi
drug
consid
potenti
chemoprevent
agent
hbvrelat
hepatocarcinogenesi
betain
natur
occur
dietari
compound
also
synthes
vivo
cholin
vivo
betain
act
methyl
donor
convers
homocystein
methionin
also
function
osmolyt
chronic
ethanol
exposur
shown
decreas
hepat
concentr
sadenosylmethionin
sam
plasma
concentr
folat
anim
human
studi
increas
plasma
concentr
homocystein
hepat
level
sadenosylhomocystein
sah
liver
betain
transfer
methyl
group
homocystein
order
form
methionin
result
decreas
concentr
homocystein
increas
concentr
methionin
liver
result
decreas
hepat
concentr
sah
wherea
latter
increas
hepat
sam
concentr
lead
increas
sam
sah
elev
sam
sah
trigger
cascad
event
lead
format
proper
vldl
export
triacylglycerol
attenu
fatti
liver
increas
hepat
concentr
sam
activ
cystathioninesynthas
lead
upregul
transsulfur
pathway
increas
synthesi
glutathion
attenu
oxid
stress
thu
betain
amelior
ald
attenu
fatti
liver
inflamm
fibrosi
role
mitochondri
dysfunct
pathogenesi
alcohol
liver
diseas
long
document
multipl
laboratori
dietari
supplement
betain
protect
ethanolinduc
loss
oxid
phosphoryl
system
protein
even
exact
mechan
protect
organel
level
known
betain
show
preserv
function
electron
transport
chain
maintain
integr
liver
protect
develop
alcohol
liver
injuri
prevent
induct
gener
moreov
specif
chang
associ
normal
hepat
sam
sah
ratio
mainten
methyl
potenti
respons
betain
supplement
chronic
ethanol
ingest
chronic
alcohol
administr
increas
gutderiv
endotoxin
portal
circul
activ
kupffer
cell
produc
sever
proinflammatori
cytokin
tumor
necrosi
interleukin
il
ethanol
administr
also
lead
synthesi
tolllik
receptor
protein
gene
express
kupffer
cell
indic
may
play
major
role
develop
alcoholinduc
liver
injuri
intragastr
ethanolf
rat
model
reproduc
patholog
featur
earli
alcoholinduc
liver
injuri
use
observ
chang
express
effect
betain
alcoholinduc
liver
injuri
anim
model
suggest
betain
prevent
alcoholinduc
liver
injuri
effect
improv
liver
function
hepatoprotect
mechan
betain
probabl
relat
inhibit
signal
pathway
rat
alcoholinduc
liver
injuri
betain
feed
decreas
level
serum
alt
ast
endotoxin
reduc
express
improv
degre
hepat
steatosi
inflamm
liver
tissu
summari
result
studi
show
express
increas
significantli
ethanolf
rat
betain
administr
inhibit
express
may
mechan
protect
alcohol
liver
injuri
exert
betain
role
betain
treatment
nash
evalu
human
studi
oral
administr
betain
glucuron
nash
patient
week
reduc
hepat
steatosi
hepatomegali
significantli
attenu
serum
concentr
ast
alt
glutamyl
transferas
similarli
mark
improv
degre
steatosi
necroinflammatori
grade
stage
fibrosi
obtain
treatment
betain
nonalcohol
fatti
liver
diseas
nafld
common
liver
diseas
associ
insulin
resist
betain
treatment
would
prevent
treat
nafld
mice
betain
reduc
fast
glucos
insulin
triglycerid
hepat
fat
mice
submit
moder
highfat
diet
mhf
betain
significantli
improv
insulin
resist
hepat
steatosi
betain
treatment
revers
inhibit
hepat
insulin
signal
mhf
insulinresist
cell
includ
normal
insulin
receptor
substrat
phosphoryl
signal
pathway
gluconeogenesi
glycogen
synthesi
conclud
betain
treatment
prevent
treat
fatti
liver
moder
highdietaryfat
model
nafl
mice
moreov
betain
supplement
allevi
hepat
patholog
chang
concomit
attenu
insulin
resist
shown
improv
homeostasi
model
assess
basal
insulin
resist
valu
glucos
toler
test
correct
abnorm
adipokin
product
adiponectin
resistin
leptin
specif
betain
supplement
enhanc
insulin
sensit
adipos
tissu
shown
improv
extracellular
signalregul
kinas
protein
kinas
b
activ
adipocyt
freshli
isol
mice
fed
highfat
diet
pretreat
betain
enhanc
insulin
signal
pathway
improv
adipokin
product
investig
use
whole
liver
tissu
reveal
betain
supplement
allevi
highfat
dietinduc
endoplasm
reticulum
stress
respons
adipos
tissu
shown
attenu
glucoseregul
protein
homolog
protein
chop
protein
abund
cjun
kinas
activ
song
et
al
show
betain
significantli
attenu
hepat
steatosi
induc
highsucros
diet
anim
model
chang
associ
increas
activ
hepat
ampactiv
protein
kinas
ampk
attenu
lipogen
capabl
enzym
activ
gene
express
liver
caus
failur
antivir
treatment
standard
therapi
pegyl
interferon
alpha
pegifnalpha
combin
ribavirin
half
patient
unknown
viral
interfer
ifnalpha
signal
transduct
jakstat
pathway
could
consid
express
hcv
protein
lead
impair
jakstat
signal
inhibit
methyl
unmethyl
less
activ
sinc
bound
inactiv
inhibitor
protein
inhibitor
activ
treatment
cell
sadenosyllmethionin
adomet
betain
could
restor
methyl
improv
ifn
alpha
signal
furthermor
antivir
effect
ifnalpha
cell
cultur
could
significantli
enhanc
addit
adomet
betain
sadenosyllmethionin
betain
potenti
signal
cultur
cell
express
hepat
c
viru
hcv
protein
enhanc
inhibitori
effect
hcv
replicon
betain
found
safe
use
conclus
addit
drug
antivir
standard
therapi
patient
chronic
hepat
c
could
overcom
problem
drug
resist
homocystein
sulfur
amino
acid
involv
methionin
metabol
belong
group
intracellular
thiol
hyperhomocysteinemia
frequent
caucasian
role
vascular
patholog
clearli
establish
hepatolog
experiment
data
transgen
mice
defici
homocystein
metabol
enzym
shown
presenc
sever
liver
steatosi
occasion
steatohepat
chronic
hepat
c
preliminari
data
shown
hyperhomocysteinemia
independ
risk
factor
steatosi
even
fibrosi
physiopatholog
mechan
begun
better
understood
one
hand
strong
correl
homocystein
insulin
resist
whatev
etiolog
hand
homocystein
direct
effect
liver
result
overexpress
favor
steatosi
stimul
proinflammatori
cytokin
secret
nf
kappa
b
increas
risk
nash
final
homocystein
could
increas
risk
fibrosi
stimul
timp
moreov
hepat
c
viru
induc
hypomethyl
stat
could
decreas
antivir
activ
interferon
result
vitro
studi
shown
normal
stat
methyl
bring
betain
adenosyl
methionin
belong
homocystein
cycl
restor
antivir
activ
interferon
final
treatment
hyperhomocysteinemia
could
favor
consequ
steatohepatit
hcv
infect
data
exist
role
betain
histolog
clinic
effect
hepatitisbvirusinfect
patient
glycyrrhiza
glabra
licoric
root
perenni
herb
cultiv
temper
subtrop
region
world
nativ
mediterranean
region
well
central
southwestern
asia
belong
leguminosa
famili
genu
glycyrrhiza
aqueou
extract
plant
contain
glycyrrizin
gl
conjug
two
molecul
glucuron
acid
one
acid
ga
substanc
flavonoid
hydroxycoumarin
betasitosterol
stronger
neominophagen
c
snmc
product
use
japan
treatment
acut
chronic
hepat
solut
administ
intraven
mgday
variabl
period
time
contain
glycyrrhizin
cystein
glycin
physiolog
solut
unit
state
glycyrrhizin
avail
multipl
nonstandard
oral
formul
found
countri
gl
inject
iv
partial
metabol
acid
liver
lysosom
gl
could
excret
bile
biliaryexcret
gl
hydrolyz
intestin
bacteria
ga
reabsorb
bloodstream
oral
administ
gl
enzymat
hydrolyz
ga
intestin
bacteri
flora
absorpt
bloodstream
circul
ga
metabol
liver
udpglucuronyl
transferas
excret
bile
intestin
pharmacokinet
characterist
iv
administr
gl
patient
liver
diseas
studi
japanes
european
report
snmc
linear
pharmacokinet
mg
steadi
state
achiev
two
week
mg
dose
administr
six
time
per
week
potenti
interact
may
occur
drug
metabol
although
report
date
decreas
potassium
sodium
retent
worsen
ascit
hypertens
possibl
advers
effect
due
dehydrogenas
inhibitori
activ
gl
ga
howev
publish
data
show
increas
rate
sideeffect
treatment
although
document
toxic
poor
report
use
gl
acut
chronic
hepat
due
hepatoprotect
immunomodulatori
antiinflammatori
effect
reduc
ischemiareperfus
ir
induc
liver
injuri
inhibit
hightmobl
group
box
inflammatori
cytokin
act
inflamm
organ
damag
hepat
irinjuri
mani
studi
shown
gl
attenu
inflammatori
respons
due
decreas
activ
nuclear
factor
kb
nfkb
mitogenactiv
protein
kinas
mapk
pathway
moreov
inhibit
product
lpsinduc
nitric
oxid
tumor
necrosi
prostaglandin
intracellular
reactiv
oxygen
speci
ro
proinflammatori
interleukin
increas
product
antiinfiammatori
interleukin
anim
studi
gl
inhibit
tcell
tumor
necrosi
factor
tnf
mediat
cytotox
activ
nk
cell
extrathym
lymphocyt
differenti
promot
matur
dendrit
cell
gl
inhibit
serum
ast
alt
level
histolog
inhibit
infiltr
inflammatori
cell
spread
degen
area
hepatocyt
anim
model
concanavalin
ainduc
liver
injuri
mani
studi
show
gl
antivir
activ
review
mechan
propos
explain
proprieti
membran
stabil
effect
demonstr
rat
hepatocyt
incub
antibodi
rais
rat
liver
cell
membran
rat
hepatocyt
releas
ast
incub
antiliv
cell
antibodi
presenc
complement
endogen
phospholipas
activ
increas
glycyrrhizin
suppress
phospholipas
activ
reduc
transaminas
level
recent
studi
confirm
proprieti
hiv
influenza
viru
despit
preced
review
evidenc
snmc
act
antiinflammatori
cytoprotect
drug
antivir
properti
recent
vitro
studi
found
gl
inhibit
hcv
fulllength
viral
particl
hcv
core
gene
express
function
dosedepend
manner
synergist
effect
interferon
european
random
trial
show
biochem
effect
treatment
snmc
patient
chronic
hepat
c
glycyrrhizinmodifi
glycosyl
block
sialyl
hepat
b
surfac
antigen
hbsag
vitro
studi
measur
releas
surfac
protein
hbsag
hbvdna
transfect
cell
show
compound
moder
abil
reduc
viral
product
longterm
clinic
trial
japan
netherland
demonstr
interferon
nonrespond
patient
chronic
hepat
c
fibrosi
stage
reduc
incid
rate
hcc
glycyrrhizin
therapi
normal
alt
level
welldiagnos
studi
need
better
defin
role
gl
hbv
hcvrelat
liver
diseas
betaglycyrrhetin
acid
suppress
activ
hepat
stellat
cell
hcss
induc
apoptosi
block
transloc
nfkappab
nucleu
furthermor
promot
prolifer
hepatocyt
rat
liver
fibrosi
ga
inhibit
type
collagen
synthesi
progress
liver
fibrosi
probabl
suppress
collagen
gene
promot
transgen
mice
express
hcv
polyprotein
fed
excess
iron
diet
snmc
prevent
hepat
steatosi
product
attenu
ultrastructur
alter
mitochondria
liver
activ
mitochondri
increas
express
carnitin
palmitoyl
transferas
decreas
product
reactiv
oxygen
speci
wu
et
al
found
biolog
activ
metabolit
gl
prevent
ffainduc
lipid
accumul
cell
apoptosi
vitro
nafld
model
also
prevent
highfatdietinduc
hepat
lipotox
liver
injuri
vivo
rat
nafld
model
ga
stabil
lysosom
membran
inhibit
cathepsin
b
express
enzym
activ
inhibit
mitochondri
cytochrom
c
releas
reduc
ffainduc
oxid
stress
recent
review
reveal
triterpenoid
also
found
glycyzirra
glabra
extract
antitumor
activ
triterpenoid
could
induc
apoptosi
variou
cancer
cell
activ
variou
proapoptot
signal
cascad
molecular
mechan
involv
includ
inhibit
variou
oncogen
antiapoptot
signal
pathway
suppress
nuclear
transloc
transcript
factor
includ
human
hepatoma
cell
line
express
junb
mrna
tumor
suppressor
gene
jung
protein
highli
increas
gl
treatment
zhao
et
al
studi
acid
function
quantum
dot
qd
found
drug
proapoptot
effect
hepatocarcinoma
cell
qd
trigger
phase
arrest
induc
apoptosi
reactiv
oxygen
speci
mediat
mitochondri
dysfunct
pathway
genu
phyllantu
euphorbiacea
consist
speci
genera
american
african
madagascar
remain
asian
australian
mani
speci
use
tradit
medicin
mainli
india
china
treat
sever
diseas
morpholog
analysi
sampl
phyllanthu
use
raw
drug
trade
southern
india
shown
market
sampl
contain
p
amaru
predomin
speci
five
differ
speci
name
p
debili
p
fraternu
p
urinaria
p
maderaspatensi
p
kozhikodianu
found
remain
shop
p
amaru
wide
studi
commonli
use
indian
ayurved
medicin
treatment
gastrointestin
genitourinari
diseas
main
activ
compon
ligan
phyllanthin
hypophyllanthin
flavonoid
alkaloid
hydrolys
tannin
polyphenol
triterperen
sterol
volatil
oil
mani
anim
studi
evidenc
hepatoprotect
activ
p
amaru
extract
enhanc
liver
serum
alanin
transaminas
alt
aspart
transaminas
ast
alkalin
phosphatas
alp
acid
phosphatas
acp
glutathion
transferas
gst
furthermor
lipid
peroxid
level
significantli
reduc
ethanol
liver
diseas
anim
model
administr
p
amaru
extract
significantli
decreas
level
collagen
tissu
inhibitor
matrix
metalloproteinas
timp
posit
modul
express
matrix
metalloproteinas
mmp
rat
alcohol
thermal
oxid
polyunsatur
fatti
acid
pufa
induc
hepat
fibrosi
mice
aflatoxin
liver
damag
p
amaru
extract
lower
content
thiobarbitur
acid
reactiv
substanc
tbarss
enhanc
reduc
glutathion
level
activ
antioxid
enzym
glutathion
peroxidas
gpx
glutathionestransferas
gst
superoxid
dismutas
sod
catalas
cat
recent
anim
studi
found
synergist
effect
silymarin
p
amaru
especi
ethano
extract
p
amaru
due
higher
concentr
phyllanthin
comparison
aqueou
extract
cclinduc
nepatotox
hepatoprotect
action
studi
also
phyllanthu
speci
p
simplex
p
atropurpureu
p
acidu
p
fraternu
p
emblica
p
urinaria
p
maderaspatensi
signific
antioxid
antiinflammatori
activ
found
especi
p
simplex
extract
high
phenol
content
final
antioxid
activ
compar
p
virgatu
p
amaru
found
first
higher
cytotox
higher
free
radic
scaveng
activ
inhibit
peroxid
capac
preclin
studi
shown
emblica
officinali
p
emblica
protect
ethanolinduc
hepatotox
review
anim
studi
show
fruit
extract
improv
plasma
enzym
level
reduc
lipid
peroxid
restor
enzymat
nonenzymat
antioxid
level
alcoholinduc
liver
diseas
action
probabl
due
tannoid
flavonoid
scaveng
compound
present
extract
phyllanthin
restor
antioxid
capabl
rat
hepatocyt
includ
level
total
glutathion
activ
superoxid
dismutas
sod
glutathion
reductas
gr
reduc
ethanol
p
amarusmodifi
alcohol
thermal
oxid
pufainduc
fibrosi
rat
decreas
level
collagen
timp
posit
modul
express
mmp
p
amaru
extract
use
preliminari
studi
involv
patient
chronic
hepat
b
treat
patient
clear
viru
week
end
treatment
period
one
placebo
treat
becam
hbsag
neg
mechan
action
appear
relat
suppress
effect
phyllanthu
extract
hbsag
secret
hbsag
mrna
express
inhibit
hepat
b
viru
polymeras
activ
recent
studi
isol
polyphenol
compound
p
emblica
found
treatment
reduc
hbsag
hbeag
level
cultur
supernat
cell
role
phyllanthu
spp
treatment
chronic
hepat
b
studi
sever
report
evalu
recent
cochran
review
author
includ
total
random
trial
one
compar
phyllanthu
placebo
found
signific
differ
hbeag
seroconvers
end
treatment
followup
fifteen
trial
compar
phyllanthu
plu
antivir
drug
like
interferon
alpha
lamivudin
adefovir
dipivoxil
thymosin
vidarabin
convent
treatment
antivir
drug
alon
found
combin
treatment
affect
serum
hbv
dna
serum
hbeag
hbeag
seroconvers
author
conclud
phyllanthu
combin
antivir
drug
may
better
antivir
drug
alon
clinic
trial
larg
sampl
size
low
risk
bia
need
confirm
find
metano
extract
p
amaru
root
leaf
also
recent
studi
treatment
chronic
hepat
c
root
extract
show
signific
inhibit
proteas
enzym
wherea
leaf
extract
show
consider
inhibit
vitro
assay
extract
significantli
inhibit
replic
hcv
monocistron
replicon
rna
hcv
viral
rna
hcv
cell
cultur
system
furthermor
addit
root
extract
togeth
show
addit
effect
inhibit
hcv
rna
replic
p
emblica
p
urinaria
phyllanthu
speci
studi
cancer
treatment
water
extract
p
urinaria
induc
apoptosi
dna
fragment
increas
activ
reduc
viabil
numer
cancer
cell
line
probabl
telomeras
suppress
activ
reduc
angiogenesi
suppress
secret
inhibit
activ
zinc
chelat
p
emblica
phytochem
gallic
acid
ellag
acid
pyrogallol
norsesquiterpenoid
corilagin
geraniin
elaeocarpusin
prodelphinidin
possess
antineoplast
effect
also
possess
properti
efficaci
treatment
prevent
cancer
radiomodulatori
chemomodulatori
chemoprevent
effect
free
radic
scaveng
antioxid
antiinflammatori
antimutagen
immunomodulatori
activ
liver
p
emblica
p
urinaria
inhibit
cell
growth
five
cancer
cell
line
progallin
isol
acet
ether
part
leav
inhibit
prolifer
cell
upregul
bax
downregul
express
defat
methanol
fruit
extract
p
emblica
suppress
carcinogeninduc
respons
rat
liver
diethylnitrosamineinduc
hepatocarcinoma
ayurved
medicin
use
year
prevent
treatment
viral
hepat
alcohol
liver
diseas
earli
cirrhosi
varieti
condit
protein
energi
malnutrit
loss
appetit
other
compos
cappari
spinosa
cichorium
intybu
mandur
bhamsa
solarium
nigrum
terminalia
arjuna
cassia
occidentali
achillea
millefolium
tamarix
gallica
potenti
cytoprotect
effect
studi
vitro
studi
improv
copper
tertbutyl
hydroperoxid
tbhp
toxic
cell
inhibit
lipid
peroxid
increas
gsh
content
antioxid
enzym
activ
anoth
recent
studi
found
abrog
ethanolinduc
suppress
ethanolinduc
gene
express
also
upregul
mrna
pretreat
low
mlkgday
higher
dose
mlkgday
revers
paracetamolinduc
liver
toxic
mice
random
control
clinic
trial
made
result
conflict
recent
doubleblind
placebocontrol
studi
report
cirrhot
patient
treat
month
significantli
better
childpugh
score
decreas
ascit
decreas
serum
alt
ast
level
compar
placebo
group
curcumin
shown
chemoprevent
chemotherapeut
properti
tumor
anim
model
clinic
trial
anticanc
effect
curcumin
document
mani
cancer
induc
apoptosi
death
receptor
mediat
pathway
mitochondri
dysfunct
also
induc
dna
damag
respons
cleav
addit
curcumin
induc
cell
cycl
arrest
downregul
protein
express
inhibit
prolifer
human
hepatocellular
carcinoma
cell
time
dosedepend
manner
glycyrrhizin
shown
success
prevent
occurr
primari
hcc
patient
hcvrelat
chronic
liver
diseas
unknown
mechan
one
princip
role
longterm
administr
glycyrrhizin
decreas
carcinogenesi
rate
seem
antiinflammatori
one
would
retriev
activ
carcinogen
process
shown
quercetin
inhibit
growth
hepatoma
cell
dose
timedepend
manner
particularli
recent
studi
quercetin
treatment
hepatoma
cell
result
chang
cell
cycl
reduc
hcc
progress
studi
involv
quercetin
hcc
analyz
cotreat
differ
chemotherapeut
studi
show
recombin
adenoviru
vector
express
human
gmcsf
gene
quercetin
synerget
suppress
hcc
cell
prolifer
induc
hcc
cell
apoptosi
suggest
possibl
use
combin
anticanc
agent
differ
studi
author
explor
effect
combin
treatment
quercetin
combin
roscovitin
hepatoma
cell
result
show
roscovitin
combin
quercetin
consid
potenti
therapeut
target
treatment
hcc
furthermor
demonstr
reactiv
oxygen
speci
product
involv
quercetininduc
apoptosi
human
hcc
cell
line
quercetin
induc
favor
chang
antioxid
defens
system
hepatoma
cell
prevent
delay
condit
favor
cellular
oxid
stress
otherwis
quercetin
induc
oxid
stress
potenti
apoptot
action
human
hepatoma
cell
chemoprevent
effect
silymarin
hcc
establish
sever
studi
use
vitro
vivo
method
exert
benefici
effect
balanc
cell
surviv
apoptosi
interf
cytokin
addit
antiinflammatori
activ
inhibitori
effect
silymarin
develop
metastas
also
detect
neoplast
diseas
silymarin
similarli
administ
adjuv
therapi
phyllantu
emblica
exhibit
varieti
pharmacolog
effect
includ
antiinflammatori
antipyret
antioxid
antimutagen
effect
activ
principl
extract
p
emblica
demonstr
antiprolif
effect
sever
cancer
cell
line
vivo
vivo
thank
abil
interfer
cell
cycl
regul
via
inhibit
cdc
phosphatas
partial
inhibit
cdc
kinas
activ
studi
examin
growth
inhibitori
effect
p
emblica
human
hepatocellular
carcinoma
synergist
effect
doxorubicin
cisplatin
effect
chemotherapeut
agent
may
modifi
combin
p
emblica
synergist
enhanc
case
depend
combin
ratio
dose
drug
given
degre
effect
combin
may
reduc
mechan
involv
interact
chemotherapeut
drug
plant
extract
remain
unclear
evalu
although
research
complementari
altern
medicin
cam
therapi
still
limit
systemat
review
reveal
suffici
evid
conclud
cam
particularli
herbal
product
examin
effect
certain
condit
reliabl
evid
potenti
therapeut
benefit
time
limit
state
knowledg
regard
side
effect
herbal
product
studi
issu
natur
product
multipl
pharmacolog
action
variou
human
physiolog
system
would
support
treatment
chronic
diseas
like
cancer
moreov
use
herbal
medicin
safe
compar
synthet
drug
studi
requir
determin
molecular
mechan
activ
ingredi
limit
avail
clinic
trial
regard
establish
safeti
establish
efficaci
sever
studi
remark
import
protect
effect
principl
antioxid
effect
use
may
help
prevent
carcinogenicityassoci
prolif
process
recent
public
toxic
side
effect
deriv
cronic
acut
use
anyway
present
side
effect
poor
ie
glycyrrizin
induc
hypokalemia
sodium
retent
increas
bodi
weight
elev
blood
pressur
final
hepat
damag
convent
drug
wide
acknowledg
physician
well
awar
import
rememb
acut
andor
chronic
liver
damag
occur
ingest
chines
herb
herbal
contain
pyrrolizidin
alkaloid
germand
greater
celandin
kava
atractyli
gummifera
callilepsi
laureola
senna
alkaloid
chaparr
mani
other
sever
herbal
identifi
caus
acut
chronic
hepat
cholestasi
druginduc
autoimmun
vascular
lesion
evenhepat
failur
tabl
oxid
stress
common
pathway
chronic
liver
diseas
differ
etiolog
viral
alcohol
cam
seem
exert
antioxid
antifibrot
effect
liver
even
histolog
proof
action
provid
studi
use
alon
associ
etiolog
causal
standard
therapi
actual
common
major
herbal
product
proof
efficaci
random
placebocontrol
clinic
trial
often
lack
anecdot
success
person
experi
frequent
drive
forc
accept
cam
popul
contrast
pharmaceut
cam
usual
distribut
food
supplement
evalu
formal
safeti
efficaci
variat
method
harvest
prepar
extract
herb
result
dramat
differ
level
certain
alkaloid
biolog
activ
substanc
structur
defin
standard
herb
countri
use
neither
regul
control
clearli
shown
herbal
product
protect
liver
oxid
injuri
promot
viru
elimin
block
fibrogenesi
inhibit
tumor
growth
activ
molecul
must
isol
test
suitabl
cultur
anim
experi
final
random
placebocontrol
studi
enabl
ration
clinic
use
agent
